Outcome data from &gt;10 000 multiple myeloma patients in the Danish and Swedish national registries

Blimark, Cecilie; Vangsted, Annette Juul; Klausen, Tobias W.; Gregersen, Henrik; Szabo, Agoston Gyula; Hermansen, Emil; Wålinder, Göran; Knut-Bojanowska, Dorota; Zang, Chenyang; Turesson, Ingemar

doi:10.1111/ejh.13707

Cited by 10 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Danish Multiple Myeloma Registry (DMMR) and the Swedish Myeloma Registry (SMR) are population-based nationwide registries, and have previously been described in detail 19 We performed a retrospective analysis of baseline characteristics of two age cohorts, patients ≥75 years or <75 years at diagnosis in both nationwide registries, and compared treatment, response, and outcome among Danish and Swedish patients in the older cohort. Further, we compared the characteristics of our older cohort with the patient populations included in the RCTs that are the foundation of Danish, Swedish and international treatment guidelines: VISTA (bortezomib, melphalan and prednisolone (VMP) versus (vs) melphalan and prednisolone (MP)), FIRST (lenalidomide and dexamethasone continuous (Rd) vs lenalidomide and dexamethasone for 18 months (Rd18) vs melphalan, prednisolone and thalidomide (MPT)), ALCYONE (daratumumab, bortezomib, melphalan and prednisolone (D-VMP) vs bortezomib, melphalan and prednisolone (VMP)) and MAIA (daratumumab, lenalidomide and dexamethasone (D-Rd) vs lenalidomide and dexamethasone (Rd)).…”

Section: Methodsmentioning

confidence: 99%

“…The Danish Multiple Myeloma Registry (DMMR) and the Swedish Myeloma Registry (SMR) are population-based nationwide registries, and have previously been described in detail. 19-21 They were established on January 1, 2005 and January 1, 2008, respectively. Both Denmark and Sweden have personal identification code systems which are unique for every citizen and enable close to 100% coverage and follow-up.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden

et al. 2022

Self Cite

View full text Add to dashboard Cite

The prevalence of multiple myeloma (MM) is increasing in the Nordic countries and the rest of the Western World. Patients aged ≥75 years at diagnosis constitute an increasing proportion of all MM patients, but are underrepresented in randomized clinical trials. There is an urgent need for studies of the characteristics, treatment and outcome in this cohort. We present data from two nationwide population-based registries of all MM patients diagnosed in Denmark January 1st 2005 until February 18th 2020, and in Sweden from January 1st 2008 until December 31st 2019, including treatment data for patients diagnosed until 2018 (Denmark) and 2019 (Sweden). In total 4647 patients were 75 years or older at diagnosis, compared to 7378 younger patients. Patients ≥75 years, comprising approximately 40% of all MM patients, are a distinct cohort with more advanced disease at diagnosis, reflected by higher ISS (International Staging System), and a higher proportion with renal failure and anemia. We find a more gradual introduction of modern medications in the older cohort than the younger, despite simultaneous changes in guidelines. Compared to the randomized controlled trials that guide the treatment of non-transplant eligible patients, we find a higher proportion of patients ≥75 years and presenting with ISS III in real world data. Nevertheless, response rates and survival are increasing, reflecting that modern treatment regimens are effective and well tolerated, also in elderly MM patients in real-world populations.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The Danish Multiple Myeloma Registry (DMMR) and the Swedish Myeloma Registry (SMR) are population-based nationwide registries, and have previously been described in detail. 19-21 They were established on January 1, 2005 and January 1, 2008, respectively. Both Denmark and Sweden have personal identification code systems which are unique for every citizen and enable close to 100% coverage and follow-up.…”

Section: Methodsmentioning

confidence: 99%

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Most participants had MM of heavy chain IgG (70.0%), light chain kappa subtype (61.0%), with measurable Mprotein (serum: 73.0%; urine: 12.0%; both: 15.0%) at baseline. Participants had received a median (range) of 5 (2)(3)(4)(5)(6)(7)(8)(9)(10)(11) prior lines of treatment. The majority of the participants were refractory to an immunomodulatory agent (IMiD; 91.0% of participants) and/or a PI (88.0% of participants).…”

Section: Participantsmentioning

confidence: 99%

“…1,2 It is associated with significant morbidity and mortality. 3,4 In Japan, the incidence of MM was 6.1 per 100,000 persons in 2018, and it is expected to increase with age. 4 Myeloma cells have a high concentration of CD38 receptors and a slower growth fraction than other hematologic malignancies, and are therefore potentially suitable targets for anti-CD38 antibody therapy.…”

Section: Introductionmentioning

confidence: 99%

“…Multiple myeloma (MM) is the second most common hematological malignancy, characterized by hyperproliferation of malignant plasma cells in bone marrow and immune dysfunction 1,2 . It is associated with significant morbidity and mortality 3,4 . In Japan, the incidence of MM was 6.1 per 100,000 persons in 2018, and it is expected to increase with age 4 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study

Sunami

Fuchida

Suzuki

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

The primary analysis of the phase 1/2 ISLANDs study in Japanese individuals with relapsed/refractory multiple myeloma (RRMM) showed that isatuximab monotherapy was well tolerated and effective, even in participants with high‐risk cytogenetic abnormalities. Here, we report a prespecified second analysis conducted 20 months after the first dosing of the last participant (ClinicalTrials.gov identifier: NCT02812706). The primary objectives were to evaluate the safety and tolerability of isatuximab in phase 1 and to evaluate the efficacy of isatuximab, including assessment of overall response rate (ORR) at the recommended dose (RD), in phase 2. In phase 1, three participants received isatuximab 10 mg/kg every week (QW) for 4 weeks/cycle followed by every 2 weeks (Q2W) and five participants received 20 mg/kg QW/Q2W. Since no dose‐limiting toxicities occurred in phase 1, 20 mg/kg QW/Q2W was identified as the RD for the phase 2 study (n = 28). At the time of data cut‐off, three participants (one in phase 1 and two in phase 2) continued to receive isatuximab; disease progression and treatment‐related adverse events were the most common reasons for treatment discontinuation. The overall safety profile was consistent with the primary analysis. One death, not related to isatuximab treatment, was reported since the first analysis. The ORR and clinical benefit rate remained unchanged from the primary analysis at 36.4% (95% confidence interval [CI]: 20.4%–54.9%) and 54.5% (95% CI: 36.4%–71.9%), respectively. The median progression‐free survival (PFS) was 5.6 months, longer than the median PFS reported in the primary analysis (4.7 months), whereas median overall survival was not reached. Overall, isatuximab 20 mg/kg QW/Q2W had an acceptable safety and tolerability profile and showed promising antitumor activity in Japanese individuals with RRMM.

show abstract

Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study

Ruotsalainen,

Lehmus,

Putkonen

et al. 2023

Ann Hematol

View full text Add to dashboard Cite

This study aimed to determine the incidence and prevalence of multiple myeloma (MM) in Finland in 2015–2019, to characterize adult patients newly diagnosed with MM, and to follow-up their overall survival (OS) and treatment patterns until the end of 2020. We sourced the data on inpatient and outpatient diagnoses, outpatient medication use, and date of death from comprehensive, nationwide registers. We identified 2037 incident patients with MM in 2015–2019. On average, the annual crude incidence was 8.8 and the age-standardized incidence (World Standard Population) was 3.3 per 100,000. The crude prevalence at the end of 2019 was 32.7 cases per 100,000 inhabitants ≥ 18 years of age. Median age of the patients at first diagnosis (index date) was 71 years, and 48% were female, the median follow-up being 2.4 years. The median OS was estimated at 4.5 years. The proportion of the patients receiving autologous stem cell transplantation (ASCT) within one year since the index date was 24%, with little variation across study years. Conversely, the proportion of all patients receiving lenalidomide within one year since the index date increased from 27 to 48% overall, and from 39 to 81% among ASCT recipients. The estimated median relapse-free survival after ASCT was 2.9 years. Information on in-hospital MM medication administrations was available for a subset of the study cohort. In this subset, 85.8% of the patients received immunomodulatory drugs and/or proteasome inhibitors within the first year after the index date.

show abstract

Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries

Cited by 10 publications

References 48 publications

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden

Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study

Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study

Contact Info

Product

Resources

About